Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis
NCT02723760Phase 1Completed
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of 99mTc-3PRGD2, sponsored by The First Hospital of Fujian Medical University. Primary endpoint: 99mTc-3PRGD2 SPECT/CT scan at 2 years. Started Nov 2015; status: completed.
02
Drugs
99mTc-3PRGD2
Beyond the preview
Go deeper on NCT02723760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723760.